Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
117
resultados
Última actualización
19/08/2026 [08:36:00]
Resultados 100 a 117 de 117
Resumen de: CN122084894A
本发明公开了基于3D打印的便携按压式磁弹微生物传感器、制备方法及检测方法，属于生物传感器技术领域；传感器包括壳体、传感芯片、检测线圈、信号采集模块；壳体内设置有气泵腔体、微通道、反应腔；传感芯片内嵌于反应腔，检测线圈环绕于反应腔外侧并与信号采集模块电连接；微通道一端与气泵腔体连通，另一端与反应腔连通；微通道设置有外部取样接口；壳体采用3D打印技术制备，通过按压气泵腔体产生的压力驱动样本沿微通道进入反应腔，进而对污水样本进行检测；本发明解决了集成化与便携性问题，适配现场即时检测；全流程封闭化操作无需样本转移，检测数据可靠性有效提升。
Resumen de: CN122081185A
本发明属于生物医药技术领域，公开了一种用于肿瘤原位表达微管抑制蛋白的工程化细菌及其应用。通过将微管抑制蛋白基因构建至表达载体，最终转入细菌，形成工程菌。该工程菌能靶向定植于肿瘤微环境，表达微管抑制蛋白，有效抑制肿瘤细胞，显著抑制实体瘤生长，且安全性优良。
Resumen de: CN122081186A
本发明公开了一种三级淋巴结构生物模型的构建方法，可以快速高效诱导原位TLS的产生，不依赖于特定的组织器官，不需要细胞编辑、转基因小鼠等复杂昂贵的制备流程，在2～3周内产生稳定、成熟、存续时间长的TLS结构，具有周期短、成本低、操作简单、可重复、安全有效的特点。
Resumen de: CN122081243A
The invention discloses an enterosalmonella choleraesuis phage SCP512 and application thereof, and belongs to the technical field of microorganisms. The Salmonella choleraesuis phage SCP512 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.47021, and the preservation date is February 4, 2026, and the Salmonella choleraesuis phage SCP512 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The invention belongs to muscular tail bacteriophage family in tail bacteriophage. The bacteriophage SCP512 has multivalent splitting decomposition characteristic, excellent biological characteristic and environmental adaptability, can destroy the formation of a pathogenic bacteria biological membrane, and can solve the technical problems of limited splitting decomposition spectrum range, insufficient coverage on common food-borne pathogenic bacteria, weak biological membrane removal capability and weak application potential in an actual food matrix of the bacteriophage in the prior art.
Resumen de: CN122095108A
Described herein are compositions, methods, and kits for detecting diarrhea-causing pathogens from a patient, food, or environmental sample. One embodiment described herein is a primer pair and probe for a multiplex polymerase chain reaction (PCR)-based assay for the detection of gastrointestinal pathogens, these gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, Norovirus, fiveleaf virus, Campylobacter strain, Clostridium difficile, Enteroaggregating Escherichia coli (EAEC), Enteropathogenic Escherichia coli (EPEC), Enterotoxigenic Escherichia coli (ETEC), Shiga-like toxin producing Escherichia coli (STEC), Shigella/Enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Escherichia coli O157, Escherichia coli O157, Escherichia coli O157, Escherichia coli O157, Escherichia coli O157, Escherichia The composition is prepared from the following raw materials: bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, listeria monocytogenes, plesiomonas shigelloides, salmonella strains, yersinia enterocolitica, vibrio strains, cryptosporidium strains, banquette sporidium, entamoeba histolytica, giardia intestinal or giardia blue. Other embodiments include methods and kits for detecting gastrointestinal pathogens.
Resumen de: CN118846069A
The invention relates to the field of medicine, in particular to a pharmaceutical composition and a preparation method and application thereof.The pharmaceutical composition comprises a first effective component, a second effective component and a pharmaceutically acceptable carrier or auxiliary material, the microbial agent comprises any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or paratyphoid bacillus, and the second effective component comprises polyinosinic acid, polycytidylic acid and vitamin. The pharmaceutical composition belongs to artificial active immunotherapy aiming at tumors, can'stimulate 'the whole immune system, enables the therapy of activating the human immune system by bacteria to kill cancer cells to be quite stable and reliable, can remarkably save and prolong the life of cancer patients, has extremely high safety and extremely small toxic and side effects, and is suitable for clinical application. And the preparation cost is low.
Resumen de: CN122074590A
The invention belongs to the technical field of feed additives, and particularly relates to a preparation method of sheep Zhuang powder, which comprises the following specific steps: preparing an astragalus extract, preparing berberine hydrochloride, and mixing for preparation. In the preparation process of the sheep strengthening powder, the feed additive is added, the feed additive effectively replaces the previous aureomycin, the antibacterial effect (MIC) of the feed additive on escherichia coli AZ1, escherichia coli 8-1 and salmonella sk77 is obviously better than that of the aureomycin, the dosage every time is smaller, animals are healthier, both pathogenic bacteria are killed, the immunity is improved, and the sheep strengthening powder is suitable for being used for preparing sheep strengthening powder. The feed is safe and compliant, has no residue and no withdrawal period, and has the effects of fattening and weight gaining and fierce eating and fierce growth.
Resumen de: CN122081529A
The invention discloses a composition for simultaneously detecting staphylococcus aureus and salmonella based on CRISPR-Cas12a/Cas12b, a method and application, and belongs to the technical field of food safety detection. Based on the characteristics of RPA isothermal amplification and preference of different Cas12 enzyme cleavage positions, a dual RPA-CRISPR-Cas12a/Cas12b detection method for staphylococcus aureus and salmonella is established through primer screening and optimization of parameters such as crRNA, reaction time and temperature, and the problem that it is difficult to detect multiple DNA targets of a Cas12 system at the same time is effectively solved. The method is good in specificity, high in sensitivity and simple in result interpretation, the detection limits of pure cultures and artificially polluted samples can reach the order of magnitude of 100 CFU/mL, detection can be completed within 1 h, and a new technical path is provided for rapid screening of food-borne pathogenic bacteria.
Resumen de: CN122084896A
本发明公开了油脂饲料添加剂中沙门氏菌的快速筛查定量检测方法，涉及饲料添加剂检测技术领域，所述检测方法包括以下步骤：基质兼容化预处理；选择性亲和富集：快速筛查通道以及定量通道；内参与矩阵响应校准。本发明通过可逆性脂质屏蔽的基质兼容化预处理，降低油脂对捕获层与检测反应的界面干扰，克服高油脂基质中游离油脂导致的抗体配体位点遮蔽、试剂吸附以及核酸酶反应抑制等问题，避免单纯强烈化学去脂带来的目标标志破坏或检测失效，在不损伤目标识别位点的前提下显著改善下游捕获与检测灵敏度，提高样品兼容性并缩短现场前处理的复杂度，利于快速质检流程落地。
Resumen de: CN122081242A
The invention discloses an enterosalmonella choleraesuis phage SCP531 and application thereof, and belongs to the technical field of microorganisms. The Salmonella choleraesuis phage SCP531 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.47020, and the preservation date is February 4, 2026, and the Salmonella choleraesuis phage SCP531 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The invention belongs to muscular tail bacteriophage family in tail bacteriophage. The bacteriophage SCP531 has broad-spectrum and high-efficiency lysis activity and excellent biological characteristics and stability, can destroy the formation of a biological membrane of pathogenic bacteria, and can solve the technical problems that in the prior art, the bacteriophage is narrow in lysis spectrum, insufficient in biological membrane removal capacity and limited in application potential in a food matrix.
Resumen de: CN122071681A
The invention discloses a recombinant engineering bacterium, a preparation method thereof and application of the recombinant engineering bacterium in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The recombinant engineering bacterium is prepared by taking salmonella typhimurium with relA and spoT gene mutations as a carrier and introducing a recombinant plasmid containing a thrombolytic enzyme coding gene into the carrier. The invention provides a recombinant engineering bacterium with biological safety, the recombinant engineering bacterium has high thrombus targeting property under a dynamic blood flow condition, various thrombus models can be specifically targeted, and the concentration of the recombinant engineering bacterium in thrombus tissues can reach more than ten thousand times of the concentration of normal tissues such as spleen, liver and the like through bacterium proliferation. Through mediated thrombus targeted therapy, thrombus can be effectively dissolved, and revascularization is achieved. The invention provides a more effective and safer treatment strategy for diseases caused by thrombus, such as myocardial infarction, cerebral apoplexy, pulmonary embolism and the like.
Resumen de: US20260137738A1
The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.
Resumen de: AU2026203336A1
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens. ay a y
Resumen de: AU2026203393A1
DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6’ of the non-reducing end of their lipid A domain by a 10 hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory 15 diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject. - 10 - ay a y - - 1
Resumen de: US20260137765A1
A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
Resumen de: US20260140114A1
The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
Nº publicación: US20260139012A1 21/05/2026
Solicitante:
SCANDINAVIAN BIOPHARMA HOLDING AB [SE]
Scandinavian Biopharma Holding AB
Resumen de: US20260139012A1
A method for increasing the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
BOPI
Sede Electrónica
